365 related articles for article (PubMed ID: 12163269)
41. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences.
Scriba TJ; zur Megede J; Glashoff RH; Treurnicht FK; Barnett SW; van Rensburg EJ
Vaccine; 2005 Jan; 23(9):1158-69. PubMed ID: 15629359
[TBL] [Abstract][Full Text] [Related]
42. Recombinant Mycobacterium bovis bacillus Calmette-Guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques.
Sixsmith JD; Panas MW; Lee S; Gillard GO; White K; Lifton MA; Balachandran H; Mach L; Miller JP; Lavine C; DeMarco CT; Tomaras GD; Gee C; Porcelli SA; Larsen MH; Frothingham R; Schmitz JE; Jacobs WR; Haynes BF; Letvin NL; Korioth-Schmitz B
Clin Vaccine Immunol; 2014 Oct; 21(10):1385-95. PubMed ID: 25080550
[TBL] [Abstract][Full Text] [Related]
43. Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques.
Nacsa J; Radaelli A; Edghill-Smith Y; Venzon D; Tsai WP; Morghen Cde G; Panicali D; Tartaglia J; Franchini G
Vaccine; 2004 Jan; 22(5-6):597-606. PubMed ID: 14741150
[TBL] [Abstract][Full Text] [Related]
44. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
[TBL] [Abstract][Full Text] [Related]
45. High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat, and vpu genes from HIV-1 Lai.
Dunn CS; Beyer C; Kieny MP; Gloeckler L; Schmitt D; Gut JP; Kirn A; Aubertin AM
Virology; 1996 Sep; 223(2):351-61. PubMed ID: 8806570
[TBL] [Abstract][Full Text] [Related]
46. Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors.
Virnik K; Nesti E; Dail C; Hockenbury M; Ni Y; Felber BK; Schief WR; Berkower I
Vaccine; 2017 May; 35(24):3272-3278. PubMed ID: 28483193
[TBL] [Abstract][Full Text] [Related]
47. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.
Patterson LJ; Malkevitch N; Pinczewski J; Venzon D; Lou Y; Peng B; Munch C; Leonard M; Richardson E; Aldrich K; Kalyanaraman VS; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(16):8607-20. PubMed ID: 12885879
[TBL] [Abstract][Full Text] [Related]
48. DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication.
Boyer JD; Robinson TM; Maciag PC; Peng X; Johnson RS; Pavlakis G; Lewis MG; Shen A; Siliciano R; Brown CR; Weiner DB; Paterson Y
Virology; 2005 Mar; 333(1):88-101. PubMed ID: 15708595
[TBL] [Abstract][Full Text] [Related]
49. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
[TBL] [Abstract][Full Text] [Related]
50. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
51. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
[TBL] [Abstract][Full Text] [Related]
52. Fatal immunopathogenesis by SIV/HIV-1 (SHIV) containing a variant form of the HIV-1SF33 env gene in juvenile and newborn rhesus macaques.
Luciw PA; Mandell CP; Himathongkham S; Li J; Low TA; Schmidt KA; Shaw KE; Cheng-Mayer C
Virology; 1999 Oct; 263(1):112-27. PubMed ID: 10544087
[TBL] [Abstract][Full Text] [Related]
53. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.
Asbach B; Kliche A; Köstler J; Perdiguero B; Esteban M; Jacobs BL; Montefiori DC; LaBranche CC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Landucci G; Forthal DN; Seaman MS; Hawkins N; Self SG; Sato A; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Francis J; Galmin L; Ding S; Heeney JL; Pantaleo G; Wagner R
J Virol; 2016 Apr; 90(8):4133-4149. PubMed ID: 26865719
[TBL] [Abstract][Full Text] [Related]
54. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
55. Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.
Gabitzsch ES; Balint-Junior JP; Xu Y; Balcaitis S; Sanders-Beer B; Karl J; Weinhold KJ; Paessler S; Jones FR
Vaccine; 2012 Nov; 30(50):7265-70. PubMed ID: 23041546
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus.
Stott EJ; Almond N; Kent K; Walker B; Hull R; Rose J; Silvera P; Sangster R; Corcoran T; Lines J; Silvera K; Luciw P; Murphy-Corb M; Momin P; Bruck C
J Gen Virol; 1998 Mar; 79 ( Pt 3)():423-32. PubMed ID: 9519819
[TBL] [Abstract][Full Text] [Related]
57. A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge.
Patterson LJ; Robey F; Muck A; Van Remoortere K; Aldrich K; Richardson E; Alvord WG; Markham PD; Cranage M; Robert-Guroff M
AIDS Res Hum Retroviruses; 2001 Jun; 17(9):837-49. PubMed ID: 11429125
[TBL] [Abstract][Full Text] [Related]
58. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
59. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.
Silvera P; Richardson MW; Greenhouse J; Yalley-Ogunro J; Shaw N; Mirchandani J; Khalili K; Zagury JF; Lewis MG; Rappaport J
J Virol; 2002 Apr; 76(8):3800-9. PubMed ID: 11907220
[TBL] [Abstract][Full Text] [Related]
60. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.
Tryniszewska E; Nacsa J; Lewis MG; Silvera P; Montefiori D; Venzon D; Hel Z; Parks RW; Moniuszko M; Tartaglia J; Smith KA; Franchini G
J Immunol; 2002 Nov; 169(9):5347-57. PubMed ID: 12391256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
